The Fine Print
The Fine Print Series goes to primary sources — the patent filing, the trial record, the regulatory document, the peer-reviewed paper — and reads what careful analysis finds between the lines.
1 - Three Misclassified Patients May Have Killed a Drug That Works
Inside InflaRx’s pyoderma gangrenosum story and why the science behind a futility-stopped trial is stronger than it looks.
The InflaRx vilobelimab Phase 3 trial in pyoderma gangrenosum was stopped for futility. The placebo arm showed a 16.7% complete closure rate — essentially impossible in true refractory PG. A landmark validation paper published in JAAD in March 2026, co-authored by the same KOLs who commented on the trial results, shows that the enrollment criterion used had a false positive rate of 6.8%. A close reading of the trial record, the PARACELSUS validation study, and the post-hoc volumetric data suggests the futility call may rest on a handful of misclassified patients in a small trial — not on a failure of the drug’s biology.
2 - Beyond INF904: What InflaRx’s Patent Filings Say About the Next Chapter
From gout to acute kidney injury to a CNS signal hiding in plain sight — a close read of six patents most investors haven’t opened.
A close read of six patents — two families, five years apart — reveals a pipeline substantially broader than the public narrative suggests. Family 2, filed August 2023 through August 2024 and published in full via the Australian national phase in February 2026, contains positive preclinical data in gout and acute kidney injury, IP claims across IgAN, lupus nephritis, CIDP, and more, and a deliberate exclusion of the CNS/Alzheimer’s patent classification that appears on every Family 1 filing. That asymmetry, combined with a pending continuation maintaining the A61P25/28 neurodegeneration code, points toward a next-generation compound — labeled here as INF9xx — that the existing drug cannot be.
3 - The Body’s Drug Disposal System — And Why It Changes Everything
Why today’s izicopan press release matters — and what most investors missed by skipping it.
A press release dropped April 9, 2026 confirming that izicopan produces no CYP3A4 inhibition — at any tested concentration, by the most rigorous available method. In plain English: it doesn’t interfere with the liver enzyme that processes most oral immunology drugs, including corticosteroids. Avacopan does — and that single difference helps explain both avacopan’s steroid-sparing limitations and its active FDA hepatotoxicity review. This piece translates the science for a non-specialist audience, traces the real-world consequences of CYP3A4 interactions from fatal drug withdrawals to a 2025 study of 7,591 JAK inhibitor patients, and makes the case that best target plus cleanest metabolism adds up to something avacopan could never credibly claim: a genuine path to steroid-free outcomes in AAV.
INF904, non-small cell lung cancer, and the upstream signal medicine keeps missing.
A March 2026 peer-reviewed paper from Amsterdam UMC and the University of Pisa assembled the most comprehensive clinical case yet made that neutrophil-driven NETosis is the primary mechanism of immune checkpoint inhibitor resistance in the largest cancer market in oncology — then proposed solutions its own evidence argues will fail. This piece reads the paper one level deeper than its authors went: explaining why navarixin failed at the wrong step in the chain, why avdoralimab's STELLAR-001 result reflects drug class rather than target failure, and why the hypoxic tumor core — the mechanism the paper never addressed — is precisely where a cell-permeable C5aR1 inhibitor has the potential to go where $20 billion in annual checkpoint revenue cannot. Add a patent cliff costing Big Pharma tens of billions in lost sales, and the fine print gets very interesting.
5 - Why Did InflaRx Put Out a Press Release About Reactive Metabolites and Liver Microsomes?
Because any serious partner or regulator — now or in the future — needs to know izicopan won't repeat avacopan's liver damage problem. The answer is now on the public record.
In the same month the FDA formally proposed withdrawing the only approved C5aR1 inhibitor — citing data manipulation and eight liver toxicity deaths — InflaRx published two highly technical press releases that most investors couldn't read and nobody publicly asked for. This piece translates both: explaining what reactive metabolites are and why they matter clinically, why the April 27, 2026 FDA withdrawal letter made the hepatotoxicity question urgent for every pharmaceutical business development team following the AAV space, and why putting the answers on the public record seven days later was not a coincidence. The SEC merger filing that documented Party E's $44 per share bid for avacopan in 2022 tells you who was paying attention then. The two press releases tell you what InflaRx needed them to know now.
6 - The Fastest Way to Answer a Ten Billion Dollar Kidney Question
Three small kidney studies. Four large kidney markets. One question that has to be answered first.
InflaRx's May 2026 corporate presentation announced proof-of-concept basket studies in atypical hemolytic uremic syndrome, IgA nephropathy, and C3 glomerulopathy — diseases affecting 2,000 and 10,000 Americans respectively. The series has covered kidney markets affecting hundreds of thousands. This article explains why that is not a contradiction: why aHUS and C3G are not commercial destinations but proof-of-concept vehicles, why the signal they generate transfers directly to DKD, lupus nephritis, membranous nephropathy, and IgAN, and why a positive renal basket readout — with one mechanism, one receptor, and the same measurable clinical output across every indication — is the fastest available path to unlocking a US market opportunity exceeding $10 billion in peak annual sales.